🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise around the world, with figures suggesting over 82 million infections each year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Gain Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in the same week. This medication, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Data and Global Access

According to data published in a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This puts it on an comparable level with the current standard treatment, which uses two antibiotics. The study included hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Doctors on the front lines have expressed positive views. The availability of a single-dose, oral treatment like this is seen as a "game-changer" for public health efforts. This is considered essential to reduce the burden of the illness for patients and to halt the transmission of extremely resistant gonorrhoea globally.